Who
Sarah Boyce
Director
Company insider
Files Form 4 as: Director, Atrium Therapeutics; Director, Contineum Therapeutics; President and CEO, Avidity Biosciences; Director, OmniAb; Director and Other, Ligand Pharmaceuticals; Director, Berkeley Lights; President, Akcea Therapeutics; Chief Business Officer, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 173
- Buys
- 2
- Sells
- 32
- Bought
- $101K
- Sold
- $35.6M
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 1 Jan 2015
- Last trade
- 18 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 22 Sep 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code F | $1.1M126,418 at $8.95 | filing |
| 18 Sep 2026filed 22 Sep 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code F | $1.1M126,418 at $8.95 | filing |
| 26 Jun 2026filed 26 Jun 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —474,861 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —386,015 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —300,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —386,015 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —300,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —425,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —400,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —200,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —300,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —165,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —425,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —300,000 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026OmniAb (NASDAQ:OABI) Stock Price Target Raised at Leerink PartnersOABI · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Sarah Boyce; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.